Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Onvatilimab |
Synonyms | |
Therapy Description |
Onvatilimab (CI-8993) is a monoclonal antibody that targets and binds to VSIR (VISTA; PD-1H) on immune cells leading to decreased VSIR-mediated signaling and potentially resulting in activation of anti-tumor immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Onvatilimab | CI 8993|CI8993|CI-8993|JNJ 61610588|JNJ61610588|JNJ-61610588 | VSIR Antibody 6 | Onvatilimab (CI-8993) is a monoclonal antibody that targets and binds to VSIR (VISTA; PD-1H) on immune cells leading to decreased VSIR-mediated signaling and potentially resulting in activation of anti-tumor immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT04475523 | Phase I | Onvatilimab | Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | Completed | USA | AUS | 0 |